Anne Winther-Larsen

List of Publications by Year
in descending order

25 papers	375 citations	858243 12 h-index	939365 18 g-index
25 all docs	25 docs citations	25 times ranked	687 citing authors

#	Article	IF	Citations
1	Biological variation of serum neurofilament light chain. Clinical Chemistry and Laboratory Medicine, 2022, 60, 569-575.	1.4	19
2	New Insights in Coagulation and Fibrinolysis in Patients with Primary Brain Cancer: A Systematic Review. Seminars in Thrombosis and Hemostasis, 2022, 48, 323-337.	1.5	3
3	Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients. BMC Cancer, 2022, 22, 63.	1.1	14
4	Hyperfibrinolysis in Patients with Solid Malignant Neoplasms: A Systematic Review. Seminars in Thrombosis and Hemostasis, 2021, 47, 581-588.	1.5	11
5	Hyponatremia as a prognostic factor in non-small cell lung cancer: a systematic review and meta-analysis. Translational Lung Cancer Research, 2021, 10, 651-661.	1.3	8
6	Hyponatremia in lung cancer: Incidence and prognostic value in a Danish population-based cohort study. Lung Cancer, 2021, 153, 42-48.	0.9	8
7	Pre-Treatment C-Reactive Protein Predicts Survival in Small Cell Lung Cancer Patients. Onco, 2021, 1, 114-123.	0.2	0
8	Pretreatment Albumin-to-Alkaline Phosphatase Ratio Is a Prognostic Marker in Lung Cancer Patients: A Registry-Based Study of 7077 Lung Cancer Patients. Cancers, 2021, 13, 6133.	1.7	9
9	Protein C deficiency; PROC gene variants in a Danish population. Thrombosis Research, 2020, 185, 153-159.	0.8	5
10	Neurofilament Light Chain as A Biomarker for Brain Metastases. Cancers, 2020, 12, 2852.	1.7	20
11	The ABO Locus is Associated with Increased Fibrin Network Formation in Patients with Stable Coronary Artery Disease. Thrombosis and Haemostasis, 2020, 120, 1248-1256.	1.8	7
12	Genomic Profiling of Circulating Tumor DNA Predicts Outcome and Demonstrates Tumor Evolution in ALK-Positive Non-Small Cell Lung Cancer Patients. Cancers, 2020, 12, 947.	1.7	20
13	Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients. Lung Cancer, 2019, 135, 92-96.	0.9	22
14	Day-to-day and within-day biological variation of cell-free DNA. EBioMedicine, 2019, 49, 284-290.	2.7	49
15	Clinical impact of direct oral anticoagulant measuring in a real-life setting. Thrombosis Research, 2019, 175, 40-45.	0.8	8
16	EGFR Gene Polymorphism Predicts Improved Outcome in Patients With EGFR Mutation-positive Nonâ€“small cell Lung Cancer Treated With Erlotinib. Clinical Lung Cancer, 2019, 20, 161-166.e1.	1.1	13
17	Reference limits for GAD65 and IA-2 autoantibodies by chemiluminescence immunoassay in Northern European adults and children. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 123-125.	0.6	0
18	A method for treatment monitoring using circulating tumour DNA in cancer patients without targetable mutations. Oncotarget, 2018, 9, 31066-31076.	0.8	18

#	Article	IF	Citations
19	¹⁸F-FDG PET/CT for Very Early Response Evaluation Predicts CT Response in Erlotinib-Treated Nonâ€“Small Cell Lung Cancer Patients: A Comparison of Assessment Methods. Journal of Nuclear Medicine, 2017, 58, 1931-1937.	2.8	16
20	Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients. British Journal of Cancer, 2017, 117, 704-709.	2.9	45
21	Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients. Translational Oncology, 2016, 9, 505-511.	1.7	13
22	Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib. Lung Cancer, 2016, 94, 81-87.	0.9	34
23	Evaluation of factors associated with loco-regional failure and survival in limited disease small cell lung cancer patients treated with chemoradiotherapy. Acta OncolÃ³gica, 2015, 54, 1574-1581.	0.8	9
24	Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib. Lung Cancer, 2015, 90, 314-320.	0.9	13
25	EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib. Lung Cancer, 2014, 85, 435-441.	0.9	11